Advertisement
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Feldman EC, Nelson RW, Reusch C, et al. Hypercalcemia and primary hyperparathyroidism. In: Canine & Feline Endocrinology. 4th ed. Saunders; 2015:579–625.
-
2.
Berger B, Feldman EC. Primary hyperparathyroidism in dogs: 21 cases (1976–1986). J Am Vet Med Assoc. 1987;191(3):350–356.
-
3.
Withrow SJ, Page R, Vail DM. Tumors of the endocrine system. In: Clinical Oncology. 5th ed. Elsevier; 2013:504–532.
-
4.
Gear RNA, Neiger R, Skelly BJS, Herrtage ME. Primary hyperparathyroidism in 29 dogs: diagnosis, treatment, outcome and associated renal failure. J Small Anim Pract. 2005;46(1):10–16.
-
5.
Rasor L, Pollard R, Feldman EC. Retrospective evaluation of three treatment methods for primary hyperparathyroidism in dogs. J Am Anim Hosp Assoc. 2007;43(2):70–77.
-
6.
Feldman EC. Disorders of the parathyroid glands. In: Textbook of Veterinary Internal Medicine. 7th ed. Saunders; 2010:1722–1742.
-
7.
Secrest S, Grimes J. Ultrasonographic size of the canine parathyroid gland may not correlate with histopathology. Vet Radiol Ultrasound. 2019;60:729–733.
-
8.
Armstrong AJ, Hauptman JG, Stanley BJ, et al. Effect of prophylactic calcitriol administration on serum ionized calcium concentrations after parathyroidectomy: 78 cases (2005–2015). J Vet Intern Med. 2018;32(1):99–106.
-
9.
Sawyer ES, Northrup NC, Schmiedt CW, et al. Outcome of 19 dogs with parathyroid carcinoma after surgical excision. Vet Comp Oncol. 2012;10(1):57–64.
-
10.
Feldman EC, Hoar B, Pollard R, Nelson RW. Pretreatment clinical and laboratory findings in dogs with primary hyperparathyroidism: 210 cases (1987–2004). J Am Vet Med Assoc. 2005;227(5):756–761.
-
11.
Ham K, Greenfield CL, Barger A, et al. Validation of a rapid parathyroid hormone assay and intraoperative measurement of parathyroid hormone in dogs with benign naturally occurring primary hyperparathyroidism. Vet Surg. 2009;38(1):122–132.
-
12.
Kishi EN, Holmes SP, Abbott JR, Bacon NJ. Functional metastatic parathyroid adenocarcinoma in a dog. Can Vet J. 2014;55(4):383–388.
-
13.
Patnaik AK, MacEwen EG, Erlandson RA, Lieberman PH, Liu SK. Mediastinal parathyroid adenocarcinoma in a dog. Vet Pathol. 1978;15(1):55–63.
-
14.
Sakals SA, Gillick MS, Kerr ME, Boston SE. Diagnosing the etiology of hypercalcemia in a dog: a case of primary hyperparathyroidism. Vet Pathol. 2010;47(3):579–581.
-
15.
Torrance AG, Mb V, Nachreiner R. Intact parathyroid hormone assay and total calcium concentration in the diagnosis of disorders of calcium metabolism in dogs. J Vet Intern Med. 1989;3(2):86–89.
-
16.
Hristova EN, Cecco S, Niemela JE, Rehak NN, Elin RJ. Analyzer-dependent differences in results for ionized calcium, ionized magnesium, sodium, and pH. Clin Chem. 1995;41(11):1649–1653.
-
17.
DeVries SE, Feldman EC, Nelson RW, Kennedy PC. Primary parathyroid gland hyperplasia in dogs: six cases (1982–1991). J Am Vet Med Assoc. 1993;202(7):1132–1136.
-
18.
Goldstein RE, Atwater DZ, Cazolli DM, Goldstein O, Wade CM, Lindblad-Toh K. Inheritance, mode of inheritance, and candidate genes for primary hyperparathyroidism in Keeshonden. J Vet Intern Med. 2007;21(1):199–203.
-
19.
Arbaugh M, Smeak D, Monnet E. Evaluation of preoperative serum concentrations of ionized calcium and parathyroid hormone as predictors of hypocalcemia following parathyroidectomy in dogs with primary hyperparathyroidism: 17 cases (2001–2009). J Am Vet Med Assoc. 2012;241(2):233–236.
-
20.
Shane E. Parathyroid Carcinoma. J Clin Endocrinol Metab. 2001;86(2):485–493.
-
21.
Wisner ER, Penninck D, Biller DS, Feldman EC, Drake C, Nyland TG. High-resolution parathyroid sonography. Vet Radiol Ultrasound. 1997;38(6):462–466.
-
22.
Wisner ER, Nyland TG. Ultrasonography of the thyroid and parathyroid glands. Vet Clin North Am Small Anim Pract. 1998;28(4):973–991.
-
23.
Liles SR, Linder KE, Cain B, Pease AP. Ultrasonography of histologically normal parathyroid glands and thyroid lobules in normocalcemic dogs. Vet Radiol Ultrasound. 2010;51(4):447–452.
-
24.
Halenka M, Karasek D, Frysak Z. Four ultrasound and clinical pictures of parathyroid carcinoma. Case Rep Endocrinol. 2012;2012:363690.
-
25.
Dear JD, Kass PH, Della Maggiore AM, Feldman EC. Association of hypercalcemia before treatment with hypocalcemia after treatment in dogs with primary hyperparathyroidism. J Vet Intern Med. 2017;31(2):349–354.
-
26.
Milovancev M, Schmiedt CW. Preoperative factors associated with postoperative hypocalcemia in dogs with primary hyperparathyroidism that underwent parathyroidectomy: 62 cases (2004–2009). J Am Vet Med Assoc. 2013;242(4):507–515.
-
27.
Rosol TJ, Meuten DJ. Tumors of the endocrine glands. In: Tumors in Domestic Animals. 5th ed. Wiley; 2020:766–834.
-
28.
Lee I-T, Sheu WH-H, Tu S-T, Kuo S-W, Pei D. Bisphosphonate pretreatment attenuates hungry bone syndrome postoperatively in subjects with primary hyperparathyroidism. J Bone Miner Metab. 2006;24(3):255–258.
-
29.
Mittendorf EA, Merlino JI, McHenry CR. Post-parathyroidectomy hypocalcemia: incidence, risk factors, and management. Am Surg. 2004;70(2):114–119.
-
30.
Headley CM. Hungry bone syndrome following parathyroidectomy. ANNA J. 1998;25(3):283–289.
-
31.
Kumar A, Ralston SH. Bisphosphonates prevent the hungry bone syndrome. Nephron. 1996;74(4):729.
-
32.
Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med. 1995;333(3):166–174.
-
33.
Okamoto T, Iihara M, Obara T, Tsukada T. Parathyroid carcinoma: etiology, diagnosis, and treatment. World J Surg. 2009;33(11):2343–2354.
-
34.
Kameyama K, Takami H. Proposal for the histological classification of parathyroid carcinoma. Endocr Pathol. 2005;16(1):49–52.
-
35.
Kiupel M, Capen C, Miller M, et al. Histological classification of tumors of the endocrine system of domestic animals. In: International Histological Classification of Tumors of Domestic Animals. Vol 12. Charles Louis Davis DVM Foundation; 2008:39–43.
-
36.
Schantz A, Castleman B. Parathyroid carcinoma. A study of 70 cases. Cancer. 1973;31(3):600–605.
-
37.
Bondeson L, Sandelin K, Grimelius L. Histopathological variables and DNA cytometry in parathyroid carcinoma. Am J Surg Pathol. 1993;17(8):820–829.
-
38.
Shane E, Bilezikian JP. Parathyroid carcinoma: a review of 62 patients. Endocr Rev. 1982;3(2):218–226.
-
39.
Juhlin CC, Nilsson I-L, Lagerstedt-Robinson K, et al. Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center. Mod Pathol. 2019;32(8):1082–1094.
-
40.
Gardner DG. Recent advances in multiple endocrine neoplasia syndromes. Adv Intern Med. 1997;42:597–627.
-
41.
Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat. 2008;29(1):22–32.
-
42.
Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer. 2005;5(5):367–375.
-
43.
Posada-González M, Gómez-Ramírez J, Luque-Ramírez M, et al. Nonfunctional metastatic parathyroid carcinoma in the setting of multiple endocrine neoplasia type 2A syndrome. Surg Res Pract. 2014;2014:731481. doi: 10.1155/2014/731481
-
44.
Thakker RV, De Groot L, Jameson JL. Multiple endocrine neoplasia type 1. In: Endocrinology. 6th ed. Elsevier; 2010:2719–2741.
-
45.
Thakker RV. Multiple endocrine neoplasiaapos;syndromes of the twentieth century. J Clin Endocrinol Metab. 1998;83(8):2617–2620.
-
46.
Jenkins PJ, Satta MA, Simmgen M, et al. Metastatic parathyroid carcinoma in the MEN2A syndrome. Clin Endocrinol (Oxf). 1997;47(6):747–751.
-
47.
Alfaro JJ, Lamas C, Estrada J, Lucas T. MEN-2A syndrome and pulmonary metastasis. Postgrad Med J. 2002;78(915): 51–52.
-
48.
von Dehn BJ, Nelson RW, Feldman EC, Griffery SM. Pheochromocytoma and hyperadrenocorticism in dogs: six cases (1982–1992). J Am Vet Med Assoc. 1995;207(3):322–324.
-
49.
Bennett PF, Norman EJ. Mitotane (o,p′-DDD) resistance in a dog with pituitary-dependent hyperadrenocorticism and phaeochromocytoma. Aust Vet J.1998;76(2):101–103.
-
50.
Thuróczy J, van Sluijs FJ, Kooistra HS, et al. Multiple endocrine neoplasias in a dog: corticotrophic tumour, bilateral adrenocortical tumours, and pheochromocytoma. Vet Q. 1998;20(2):56–61.
-
51.
Walker MC, Jones BR, Guildford WG, Burbidge HM, Alley MR. Multiple endocrine neoplasia type 1 in a crossbred dog. J Small Anim Pract. 2000;41(2):67–70.
-
52.
Beatrice L, Boretti FS, Sieber-Ruckstuhl NS, et al. Concurrent endocrine neoplasias in dogs and cats: a retrospective study (2004–2014). Vet Rec. 2018;182(11):323.
-
53.
Peterson ME, Randolph JF, Zaki FA, Heath H III. Multiple endocrine neoplasia in a dog. J Am Vet Med Assoc. 1982;180(12):1476–1478.
-
54.
Wright KN, Breitschwerdt EB, Feldman JM, Berry CR, Meuten GJ, Spodnick GJ. Diagnostic and therapeutic considerations in a hypercalcemic dog with multiple endocrine neoplasia. J Am Anim Hosp Assoc. 1995;31(2):156–162.
-
55.
Kiupel M, Mueller PB, Ramos Vara J, Irizarry A, Lin TL. Multiple endocrine neoplasia in a dog. J Comp Pathol. 2000;123(2–3):210–217.
-
56.
Proverbio D, Spada E, Perego R, et al. Potential variant of multiple endocrine neoplasia in a dog. J Am Anim Hosp Assoc. 2012;48(2):132–138.
-
57.
Hoenerhoff M, Kiupel M. Concurrent gastrinoma and somatostatinoma in a 10-year-old Portuguese water dog. J Comp Pathol. 2004;130(4):313–318.
-
58.
Feldman EC, Nelson RW. Canine thyroid tumors and hyperthyroidism. In: Canine and Feline Endocrinology and Reproduction. 3rd ed. Saunders; 2004:220–249.
-
59.
Cetani F, Pardi E, Marcocci C. Parathyroid carcinoma. Front Horm Res. 2019;51:63–76.
-
60.
Long CD, Goldstein RE, Hornof WJ, Feldman EC, Nyland TG. Percutaneous ultrasound-guided chemical parathyroid ablation for treatment of primary hyperparathyroidism in dogs. J Am Vet Med Assoc. 1999;215(2):217–221.
-
61.
Pollard RE, Long CD, Nelson RW, Hornof WJ, Feldman EC. Percutaneous ultrasonographically guided radiofrequency heat ablation for treatment of primary hyperparathyroidism in dogs. J Am Vet Med Assoc. 2001;218(7):1106–1110.
-
62.
Guttin T, Knox VW, Diroff JS. Outcomes for dogs with primary hyperparathyroidism following treatment with percutaneous ultrasound-guided ethanol ablation of presumed functional parathyroid nodules: 27 cases (2008–2011). J Am Vet Med Assoc. 2015;247(7):771–777.
Advertisement
Incidence, survival time, and surgical treatment of parathyroid carcinomas in dogs: 100 cases (2010–2019)
Abstract
OBJECTIVE
To evaluate outcomes of dogs with parathyroid carcinoma (PTC) treated by surgical excision and to describe the incidence of postoperative hypocalcemia, degree of hypocalcemia, duration of hospitalization, duration of calcium supplementation, and survival time
ANIMALS
100 client-owned dogs with PTC admitted to academic, referral veterinary institutions.
PROCEDURES
In a retrospective multi-institutional study, medical records of dogs undergoing surgical excision of PTC between 2010 to 2019 were reviewed. Signalment, relevant medical history, clinical signs, clinicopathologic testing, imaging, surgical findings, intraoperative complications, histologic examination, and survival time were recorded.
RESULTS
100 dogs with PTC were included, and 96 dogs had clinical or incidental hypercalcemia. Common clinical signs included polyuria (44%), polydipsia (43%), hind limb paresis (22%), lethargy (21%), and hyporexia (20%). Cervical ultrasonography detected a parathyroid nodule in 91 of 91 dogs, with a single nodule in 70.3% (64/91), 2 nodules in 25.3% (23/91), and ≥ 3 nodules in 4 (4/91)% of dogs. Hypercalcemia resolved in 89 of 96 dogs within 7 days after surgery. Thirty-four percent of dogs developed hypocalcemia, on the basis of individual analyzer ranges, within 1 week after surgery. One dog had metastatic PTC to the prescapular lymph node, and 3 dogs were euthanized for refractory postoperative hypocalcemia. Estimated 1-, 2-, and 3-year survival rates were 84%, 65%, and 51% respectively, with a median survival time of 2 years.
CONCLUSIONS AND CLINICAL RELEVANCE
Excision of PTC results in resolution of hypercalcemia and excellent long-term tumor control. Surgical excision of PTC is recommended because of resolution of hypercalcemia and a good long-term prognosis. Future prospective studies and long-term follow-up are needed to further assess primary tumor recurrence, metastasis, and incidence of postoperative hypocalcemia.
Contributor Notes
Powered by PubFactory